Candel Therapeutics (CADL) Share-based Compensation (2020 - 2025)
Candel Therapeutics recorded quarterly Share-based Compensation of $1.3 million in Q4 2025, up 10.92% quarter-over-quarter from $1.2 million in Q3 2025, and up 3.7% year-over-year from $1.2 million in Q4 2024.
Candel Therapeutics' Share-based Compensation history runs 6 years deep, the most recent figure standing at $1.3 million for Q4 2025.
- In Q4 2025, Share-based Compensation rose 3.7% year-over-year to $1.3 million; the TTM figure through Dec 2025 stood at $3.8 million (down 28.14% YoY), while the FY2025 annual figure was $3.8 million, down 28.14% from the prior year.
- Share-based Compensation came in at $1.3 million for Q4 2025 at Candel Therapeutics, up from $1.2 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $1.9 million in Q3 2021 to a low of -$446000.0 in Q4 2021.
- A 5-year average of $874500.0 and a median of $841000.0 in 2022 frame the typical range for Share-based Compensation.
- On a YoY basis, Share-based Compensation climbed as much as 2200.0% in 2021 and fell as far as 125.44% in 2021.
- Candel Therapeutics' Share-based Compensation stood at -$446000.0 in 2021, then surged by 242.15% to $634000.0 in 2022, then surged by 48.11% to $939000.0 in 2023, then jumped by 32.48% to $1.2 million in 2024, then grew by 3.7% to $1.3 million in 2025.
- According to Business Quant data, Share-based Compensation over the past three periods registered $1.3 million, $1.2 million, and $1.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 257.40 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.15 Mn |
| 10 | Candel Therapeutics | 449.62 Mn | 449.62 Mn | - | 1.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.29 Mn |
| Dec 31, 2025 | 1.29 Mn |
| Sep 30, 2025 | 1.16 Mn |
| Sep 30, 2025 | 1.16 Mn |
| Jun 30, 2025 | 1.05 Mn |
| Jun 30, 2025 | 1.05 Mn |
| Mar 31, 2025 | 314,000.00 |
| Mar 31, 2025 | 314,000.00 |
| Dec 31, 2024 | 1.24 Mn |
| Dec 31, 2024 | 1.24 Mn |
| Sep 30, 2024 | 1.18 Mn |
| Sep 30, 2024 | 1.18 Mn |
| Jun 30, 2024 | 1.84 Mn |
| Jun 30, 2024 | 1.84 Mn |
| Mar 31, 2024 | 1.04 Mn |
| Mar 31, 2024 | 1.04 Mn |
| Dec 31, 2023 | 939,000.00 |
| Dec 31, 2023 | 939,000.00 |
| Sep 30, 2023 | 686,000.00 |
| Sep 30, 2023 | 686,000.00 |
| Jun 30, 2023 | 733,000.00 |
| Jun 30, 2023 | 733,000.00 |
| Mar 31, 2023 | 733,000.00 |
| Mar 31, 2023 | 733,000.00 |
| Dec 31, 2022 | 634,000.00 |
| Dec 31, 2022 | 634,000.00 |
| Sep 30, 2022 | 743,000.00 |
| Sep 30, 2022 | 743,000.00 |
| Jun 30, 2022 | 438,000.00 |
| Jun 30, 2022 | 438,000.00 |
| Mar 31, 2022 | 492,000.00 |
| Mar 31, 2022 | 492,000.00 |
| Dec 31, 2021 | -446,000.00 |
| Dec 31, 2021 | -446,000.00 |
| Sep 30, 2021 | 1.91 Mn |
| Sep 30, 2021 | 1.91 Mn |
| Jun 30, 2021 | 1.07 Mn |
| Jun 30, 2021 | 1.07 Mn |
| Mar 31, 2021 | 431,000.00 |
| Mar 31, 2021 | 431,000.00 |
| Dec 31, 2020 | 1.75 Mn |
| Dec 31, 2020 | 1.75 Mn |
| Sep 30, 2020 | 83,000.00 |
| Sep 30, 2020 | 83,000.00 |
| Jun 30, 2020 | 303,000.00 |
| Jun 30, 2020 | 303,000.00 |